Mixed dyslipidemias in primary care patients in France
Laurent Laforest1, Baishali M Ambegaonkar2, Thierry Souchet3, Vasilisa Sazonov2, Eric Van Ganse1
1Lyon University, Lyon, France; 2Merck and Co Inc, Whitehouse Station, NJ, USA; 3Merck, Sharp & Dohme, Paris, France
Objective: To determine the prevalence of single and mixed dyslipidemias among patients treated with statins in clinical practice in France.
Methods: This is a prospective, observational, cross-sectional, pharmacoepidemiologic study with a total of 2544 consecutive patients treated with a statin for at least 6 months.
Main outcome measures: Prevalence of isolated and mixed dyslipidemias of low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides among all patients and among patients at high cardiovascular risk; clinical variables associated with attainment of lipid targets/normal levels in French national guidelines.
Results: At least one dyslipidemia was present in 50.8% of all patients and in 71.1% of high-risk patients. Dyslipidemias of LDL-C, HDL-C, and triglycerides were present in 27.7%, 12.4%, and 28.7% of all patients, respectively, and in 51.0%, 18.2%, and 32.5% of high-risk patients, respectively. Among all subjects with any dyslipidemia, 30.9% had mixed dyslipidemias and 69.4% had low HDL-C and/or elevated triglycerides, while 30.6% had isolated elevated LDL-C; corresponding values for high-risk patients were 36.8%, 58.9%, and 41.1%. Age, gender, body mass index and Framingham Risk Score >20% were the factors significantly associated with attainment of normal levels for ≥2 lipid levels.
Conclusions: At least one dyslipidemia persisted in half of all patients and two-thirds of high cardiovascular risk patients treated with a statin. Dyslipidemias of HDL-C and/or triglycerides were as prevalent as elevated LDL-C among high cardiovascular risk patients.
Keywords: cholesterol, triglycerides, dyslipidemias, prevalence, treatment outcome, France
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Single-nucleotide polymorphisms of microRNA processing machinery genes are associated with risk for gastric cancer
Xie Y, Wang Y, Zhao Y, Guo Z
Published Date: 4 March 2015
DiNicolantonio JJ, O’Keefe JH
Published Date: 30 August 2014
A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study
Hassanein M, Abdallah K, Schweizer A
Published Date: 28 May 2014
Mahamid M, Francis A, Abid A, Awawde M, Abu-Elhija O
Published Date: 30 April 2014
Lichtenberg M, Käunicke M, Hailer B
Published Date: 4 May 2012
Gonzalo N, Macaya C
Published Date: 29 February 2012
Published Date: 2 November 2010
Luciano Babuin, Vittorio Pengo
Published Date: 1 September 2010
Michael McGillion, Allison Cook, J Charles Victor, et al
Published Date: 26 August 2010
Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al
Published Date: 22 June 2010